Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism
New Variants Also Make SARS-CoV2 A Moving Target
After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.
You may also be interested in...
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
Key committee was asked to fast-track a decision on the antibody cocktail, but lack of mortality data could mean patchy uptake seen in US repeated in the EU.
Former US FDA commissioners say that data for Lilly and Regeneron’s authorized mABs suggesting that reduced viral load correlates with clinical benefit potentially paves the way for emergency authorization or accelerated approval of mABs specifically designed to target emerging variants of the SARS-CoV-2 virus.